Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old

Reproductive Biology and Endocrinology

Volumn 13, Issue 1, 2015, Pages

  Tartagni, Massimo ^a   Cicinelli, Maria V ^b   Baldini, Domenico ^b   Tartagni, Mario V ^b   Alrasheed, Hala ^b   DeSalvia, Maria A ^a   Loverro, Giuseppe ^a   Montagnani, Monica ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b Centro di Fecondazione Medicalmente Assistita MoMo Fertilife   (Italy)

Author keywords

Dehydroepiandrosterone (DHEA); IVF parameters; Pregnancy rate

Indexed keywords

PLACEBO; PRASTERONE; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; TRIPTORELIN;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EMBRYO TRANSFER; ENDOMETRIAL THICKNESS; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; LIVE BIRTH; MAJOR CLINICAL STUDY; METAPHASE; OOCYTE RETRIEVAL; OVARIAN RESERVE; OVARY FOLLICLE; OVARY STIMULATION; OVULATION INDUCTION; PREGNANCY; PREGNANCY OUTCOME; RANDOMIZED CONTROLLED TRIAL; REPRODUCTIVE HEALTH; REPRODUCTIVE PROCEDURE; SPONTANEOUS ABORTION; IN VITRO FERTILIZATION; PREGNANCY RATE; TREATMENT OUTCOME;

ADULT; AGE FACTORS; DEHYDROEPIANDROSTERONE; DOUBLE-BLIND METHOD; FEMALE; FERTILIZATION IN VITRO; HUMANS; OVARIAN RESERVE; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY RATE; TREATMENT OUTCOME;

EID: 84925234833     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/s12958-015-0014-3     Document Type: Article

References (34)

1. Cabry R, Merviel P, Hazout A, Belloc S, Dalleac A, Copin H, et al. Management of infertility in women over 40. Maturitas. 2014;78:17-21.
2. Arlt W. Dehydroepiandrosterone and ageing. Best Pract Res Clin Endocrinol Metab. 2004;18:363-80.
3. Yakin K, Urman B. DHEA as a miracle drug in the treatment of poor responders; hype or hope? Hum Reprod. 2011;26:1941-4.
4. Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet. 2007;24:629-34.
5. Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod. 2006;21:2845-9.
6. Barad DH, Gleicher N. Increased oocyte production after treatment with dehydroepiandrosterone. Fertil Steril. 2005;84:756.
7. Gleicher N, Ryan E, Weghofer A, Blanco-Mejia S, Barad DH. Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reprod Biol Endocrinol. 2009;7:108.
8. Mamas L, Mamas E. Premature ovarian failure and dehydroepiandrosterone. Fertil Steril. 2009;91:644-6.
9. Mamas L, Mamas E. Dehydroepiandrosterone supplementation in assisted reproduction: rationale and results. Curr Opin Obstet Gynecol. 2009;21:306-8.
10. Gleicher N, Weghofer A, Barad DH. Improvement in diminished ovarian reserve after dehydroepiandrosterone supplementation. Reprod Biomed Online. 2010;21:360-5.
11. Gleicher N, Weghofer A, Barad DH. Dehydroepiandrosterone (DHEA) reduces embryo aneuploidy: direct evidence from preimplantation genetic screening (PGS). Reprod Biol Endocrinol. 2010;8:140.
12. Brill HBD, Gleicher N. Dehydroepiandrosterone (DHEA) supplementation and pregnancy outcome: effect on pregnancy rate and speed of conception. Fertil Steril. 2006;86:S124.
13. Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum Reprod. 2000;15:2129-32.
14. Evers JL. Publication bias in reproductive research. Hum Reprod. 2000;15:2063-6.
15. Tartagni M, De Pergola G, Damiani GR, Pellegrino A, Baldini D, Tartagni MV, et al. Potential benefit of Dehydroepiandrosterone supplementation for infertile but not poor responder patients in a IVF program. Minerva Ginecol. 2014;67(1):7-12.
16. Parasrampuria J, Schwartz K, Petesch R. Quality control of dehydroepiandrosterone dietary supplement products. JAMA. 1998;280:1565.
17. Thompson RD, Carlson M. Liquid chromatographic determination of dehydroepiandrosterone (DHEA) in dietary supplement products. J AOAC Int. 2000;83:847-57.
18. Committee ACoOaGCoGPaP. Female age-related fertility decline. Committee Opinion No. 589. Fertil Steril. 2014;101:633-4.
19. Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum Reprod. 2010;25:2496-500.
20. Narkwichean A, Maalouf W, Campbell BK, Jayaprakasan K. Efficacy of dehydroepiandrosterone to improve ovarian response in women with diminished ovarian reserve: a meta-analysis. Reprod Biol Endocrinol. 2013;11:44.
21. Aerts JM, Bols PE. Ovarian follicular dynamics. A review with emphasis on the bovine species. Part II: Antral development, exogenous influence and future prospects. Reprod Domest Anim. 2010;45:180-7.
22. Gleicher N, Weghofer A, Barad DH. The role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment? Reprod Biol Endocrinol. 2011;9:116.
23. Gleicher N, Weghofer A, Lee IH, Barad DH. Association of FMR1 genotypes with in vitro fertilization (IVF) outcomes based on ethnicity/race. PLoS One. 2011;6:e18781.
24. Li M, Schatten H, Sun QY. Androgen receptor's destiny in mammalian oocytes: a new hypothesis. Mol Hum Reprod. 2009;15:149-54.
25. Haning Jr RV, Hackett RJ, Flood CA, Loughlin JS, Zhao QY, Longcope C. Plasma dehydroepiandrosterone sulfate serves as a prehormone for 48% of follicular fluid testosterone during treatment with menotropins. J Clin Endocrinol Metab. 1993;76:1301-7.
26. Casson PR, Santoro N, Elkind-Hirsch K, Carson SA, Hornsby PJ, Abraham G, et al. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. Fertil Steril. 1998;70:107-10.
27. Humaidan P, Bungum M, Bungum L, Yding Andersen C. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reprod Biomed Online. 2004;8:635-43.
28. Hillier SG. Gonadotropic control of ovarian follicular growth and development. Mol Cell Endocrinol. 2001;179:39-46.
29. Lossl K, Andersen AN, Loft A, Freiesleben NL, Bangsboll S, Andersen CY. Androgen priming using aromatase inhibitor and hCG during early-follicular-phase GnRH antagonist down-regulation in modified antagonist protocols. Hum Reprod. 2006;21:2593-600.
30. Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF. DHEA and DHEA-S: a review. J Clin Pharmacol. 1999;39:327-48.
31. Morales C, Sanchez A, Bruguera J, Margarit E, Borrell A, Borobio V, et al. Cytogenetic study of spontaneous abortions using semi-direct analysis of chorionic villi samples detects the broadest spectrum of chromosome abnormalities. Am J Med Genet A. 2008;146A:66-70.
32. Pal L, Santoro N. Age-related decline in fertility. Endocrinol Metab Clin North Am. 2003;32:669-88.
33. Golbus MS, Loughman WD, Epstein CJ, Halbasch G, Stephens JD, Hall BD. Prenatal genetic diagnosis in 3000 amniocenteses. N Engl J Med. 1979;300:157-63.
34. Bettio D, Venci A, Levi Setti PE. Chromosomal abnormalities in miscarriages after different assisted reproduction procedures. Placenta. 2008;29(Suppl B):126-8.